Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 43 min 57 sec ago

Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices

Tue, 07/15/2014 - 13:05
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--Mystic Pharmaceuticals, Inc. today announced the availability of its Javelin Sublingual™ drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s VersiDoser® and VRx2™ platform techno...
Biopharmaceuticlas, Drug Delivery, Product Launch
Mystic Pharmaceuticals, Javelin Sublingual, VersiDoser, VRx2

Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence

Tue, 07/15/2014 - 12:59
Pradaxa® is as effective as warfarin in the treatment and secondary prevention of DVT and PE with significantly fewer major, or clinically relevant non-major bleeds, compared to warfarin1,2 BRACKNELL, England, July 15, 2014 -- (Healthcare Sales & Ma...
Biopharmaceuticals, Regulatory
Boehringer Ingelheim, Pradaxa, dabigatran, DVT, Pulmonary Embolism

FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

Tue, 07/15/2014 - 12:44
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics Lic...
Biopharmaceuticals, Oncology, FDA
Genentech, Roche Group, Avastin, bevacizumab, cervical cancer

Boston Scientific Receives CE Mark For Ranger(TM) Drug-Coated Balloon

Mon, 07/14/2014 - 16:04
Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease MARLBOROUGH, Mass., July 14, 2014 -- (Healthcare Sales & Marketing Network) -- Demonstrating its continued leadership in the development of innov...
Devices, Interventional, Regulatory
Boston Scientific, Ranger, Paclitaxel-Coated PTA Balloon

Intact Vascular, Inc. Hires Bruce Shook as President and Chief Executive Officer

Mon, 07/14/2014 - 16:01
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Bruce J. Shook is joining the Company as President and Chief Executive Off...
Devices, Interventional, Personnel
Intact Vascular, Tack-It Endovascular System

MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors

Mon, 07/14/2014 - 15:39
Drs. Venter, Hariri and Diamandis United in Another Ground-Breaking Biotechnology Enterprise CEDAR KNOLLS, NJ--(Healthcare Sales & Marketing Network) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherape...
Biopharmaceuticals, Personnel
MYOS Corp, Fortetropin, myostatin inhibitor

Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction

Mon, 07/14/2014 - 13:01
Brings Differentiated, Attractive Product Portfolio and Enhanced Commercial Platform, Diversifying Mylan's Business and Adding New Sales Channels in Acquired Markets Immediately and Significantly Accretive to Earnings, with Opportunity to Accelerate Tar...
Biopharmaceuticals, Generics, Acquisitions
Mylan, Abbott

Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan

Mon, 07/14/2014 - 12:54
ABBOTT PARK, Ill., July 14, 2014 (Healthcare Sales & Marketing Network) -- Abbott (ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combi...
Biopharmaceuticals, Generics, Acquisitions
Abbott, Mylan

MGC Diagnostics Corporation Completes Agreement to Acquire Medisoft SA

Mon, 07/14/2014 - 12:48
Positions MGCD as a global leader in Cardiorespiratory diagnostic products SAINT PAUL, Minn., July 14, 2014 -- (Healthcare Sales & Marketing Network) -- MGC Diagnostics Corporation (MGCD), a leading global medical technologies company, today announced ...
Diagnostics, Mergers & Acquisitions
MGC Diagnostics, Medisoft SA

Titan Spine Receives FDA Clearance to Launch Endoskeleton(R) TL Device for Lateral Spinal Fusion

Mon, 07/14/2014 - 12:41
First Surgeries Conducted by Kade Huntsman, M.D. MEQUON, Wis.--(Healthcare Sales & Marketing Network)--Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it ha...
Devices, Neurosurgery, Orthopaedic, FDA
Titan Spine, Endoskeleton TL, lateral fusion device, spine surgery

Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

Mon, 07/14/2014 - 12:32
Data from the coBRIM study will be presented at an upcoming medical meeting Genentech plans to submit these data to the U.S. Food and Drug Administration (FDA) SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member...
Biopharmaceuticals, Oncology
Genentech, Roche Group, cobimetinib, Zelboraf, melanoma, MEK inhibitor

Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer

Fri, 07/11/2014 - 12:41
TORONTO , July 11, 2014 (Healthcare Sales & Marketing Network) - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl ...
Biopharmaceuticals, Personnel
Transition Therapeutics

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1

Fri, 07/11/2014 - 12:34
Ipsen and Galderma to expand their current distribution agreement for Dysport®/Azzalure® in aesthetic and dermatology indications to the US and Canada Ipsen and Galderma to collaborate on development and commercialization of new neurotoxins, inc...
Biopharmaceuticals, Dermatology, Distribution
Ipsen, Galderma, Dysport, Azzalure

Cook Medical Reintroduces Its Evolution(R) RL Lead Extraction Products to the United States Market

Thu, 07/10/2014 - 15:19
VANDERGRIFT, Pa.--(Healthcare Sales & Marketing Network)--Effective immediately, Cook Medical customers in the United States will again have access to its Evolution® RL and Evolution® Shortie RL Controlled-Rotation Dilator Sheath Sets. Distribution...
Devices, Cardiology, Product Launch
Cook Medical, Lead Extraction, pacemaker lead

Blue Belt Enters into a Commercial Agreement with Smith and Nephew to Bring the JOURNEY UNI Knee to the Navio(R) Surgical System

Thu, 07/10/2014 - 15:16
MINNEAPOLIS--(Healthcare Sales & Marketing Network)--Blue Belt Technologies, a robotics-assisted surgical technology company, today announced a world-wide commercial agreement with Smith & Nephew, a global medical technology business, to support their JOUR...
Devices, Orthopaedic
Blue Belt Technologies, Smith & Nephew, Navio Surgical System, partial knee

CryoLife Appoints Pat Mackin as President and Chief Executive Officer

Thu, 07/10/2014 - 15:13
ATLANTA, July 10, 2014 -- (Healthcare Sales & Marketing Network) -- CryoLife, Inc. (CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has appointed James Patri...
Devices, Surgery, Personnel
CryoLife, BioGlue, Surgical Adhesive, CryoValve

Smith and Nephew enters commercial agreement to bring robotic navigation to the JOURNEY UNI Knee procedure

Thu, 07/10/2014 - 15:09
LONDON, July 10, 2014 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announced a new commercial agreement with Blue Belt Technologies (BBT), makers of the Navio® Orthopae...
Devices, Orthopaedic
Smith & Nephew, Blue Belt Technologies, JOURNEY UNI, partial knee

Vertex Announces Retirement of Peter Mueller, Ph.D.

Thu, 07/10/2014 - 15:04
BOSTON--(Healthcare Sales & Marketing Network)--Vertex Pharmaceuticals Incorporated (VRTX) today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 y...
Biopharmaceuticals, Personnel
Vertex Pharmaceuticals

Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer

Thu, 07/10/2014 - 14:47
Strong Leadership Team in Place to Advance Novel Immunotherapy Programs CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies, today announ...
Biopharmaceuticals, Oncology, Personnel
Jounce Therapeutics, immunotherapy

CIMTEC announces spin-off company Focal Healthcare, Inc. to develop the new "gold standard" of targeted prostate biopsy and therapy devices for the management of prostate cancer

Wed, 07/09/2014 - 15:01
LONDON, ON , July 9, 2014 (Healthcare Sales & Marketing Network) - Focal Healthcare (Focal) was founded as a spin-off company out of the Centre for Imaging Technology Commercialization (CIMTEC). Focal is developing and marketing MRI-Ultrasound Fusion Biop...
Devices, Oncology, Urology
Focal Healthcare, CIMTEC, imaging, Fusion Biopsy, prostate cancer

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong